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FLU, CLO, Ara-C and VP-16) and MOLT-4 was relatively sen-
sitive to tested agents showing lowest or lower IC50 than
those of other cell lines (14.2, 0.89, 0.28, 0.021, 0.0044 and
0.017 micro M respectively).
BU, MEL, FLU, CLO and Ara-C showed similar activities
against myeloid leukemia cells and lymphoid leukemia cells
[Fig 1 A)-E)]. On the other hand, VP-16 showed more anti-
leukemia activities against lymphoid leukemia cells than
myeloid leukemia cells [Fig 1 F)].
Conclusion: Although the number of tested cell lines is
limited, BU showed similar anti-leukemic activities against
myeloid and lymphoid leukemia cell lines as is shown byMEL,
FLU, CLO, and Ara-C. This data supports the use of busulfan as
a preparative agent in patients with lymphoid malignancies.
Further studies including combination of multiple chemo-
therapeutic agents would show more advanced scientiﬁc
rationale for strategic conditioning regimen of HSCT for
leukemia.245
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Acute myeloid leukemia/Myelodysplastic syndrome (AML/
MDS) is highly heterogeneous disease and prediction ofTable 1
Patient Characteristics N (%)
Number (AML/MDS) 54 (48/6)
Median Age (Range), years 56.5 (33-73)
Status at Transplant
CR1 (Complete remission -1) 32 (59%)
CR2 (Complete remission -2) 2 (4%)
P1F, REL (primary refractory, Relapse) 20 (37%)
Donor Source
Matched Related Donor 13 (24%)
Mismatched related Donor 1 (2%)
Matched Unrelated Donor 35 (65%)
Mismatched Unrelated Donor 3 (5%)
Haplo-Identical 2 (4%)
C1BMTR Risk
High 17 (31%)
Intermediate 2 (4%)
Low 35 (65%)
Cytogenetics Risk
High 30 (55%)
Low 24 (45%)
Conditioning Regimen Intensity
FtC (Full Intensity) 37 (69%)
RIC( Reduced Intensity) 17 (31%)
Conditioning Regimen
FluBU4 35 (65%)
FLuBU-PTCY 2(4%)
FluBU2 16 (29%)
CyTBI (Cytoxan/TBI) 1(2%)
Chimerism at Day 30
>95% 51 (94%)
<90% 3 (6%)
CD34 Infused X million/Kg (Range) 2.37-16
Median (million/Kg) 5.96
Median to WBC engraftment 12
Median to Plat engraftment 18
Figure 1.relapse at the molecular level is a challenging task post
allogeneic HCT. Signiﬁcant existing data supports the MCP-1/
CCR2 axis expression in the majority of AML blasts and it has
been shown to be involved in blasts trafﬁcking and prolif-
eration. To evaluate the role of MCP-1 in prediction of AML/
MDS relapse post allogeneic HCT, we measured the serum
values of MCP-1 at day 30 post HCT in 54 consecutive pa-
tients with AML/MDS using multiple luminex ELISA assay.
The samples were collected from the patients prospectively
Results: Patient characteristics are shown in Table 1.
Median age at transplant was 56 year old. GVHD
prophylaxis was Tacrolimus/Methotrexate for FIC and
Tacrolimus/ Mycophenolate for RIC. Thymoglobulin was
added at dose of 4.5 mg/Kg total dose for matched
unrelated donor recipients. All the patients engrafted with
no graft failure. Full chimerism at day 30 (> 95%) was
achieved in 51/54 patients supported by morphological
evidence of complete remission. With median follow up of
17 months, overall survival at 1 & 2 years was 78% and 67%.
Cumulative incidence of relapse at 1 year was 31% +/- 6%
while cumulative incidence of treatment related mortality
(TRM) at 2 years was 10% +/- 4%. In order to evaluate the
impact of MCP-1 levels at day 30 post HCT in predicting
relapse, patients with less than 95% chimerism (n¼3) and
patients who died as result of TRM prior to relapse (n¼5)
were excluded from the analysis. At day 30 post HCT,
patients with full chimerism who relapsed (n¼13) had
higher mean MCP-1 level of 514 +/- 175 versus patients
with full chimerism who did not relapse (n¼33), mean
MCP-1 level of 382 +/-181; P¼ 0.03. (Figure 1). The median
Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205S190time to relapse from day 30 post-transplant was 69 days
(range 41-230 days). The cumulative incidence of acute
GVHD grade II-IV was 44% with 10% grade III-IV. The
cumulative incidence of chronic GVHD at 2 years was 48%,
with 22% extensive chronic GVHD.
Conclusion: In this cohort of patients with AML/ MDS,
MCP-1 levels at day 30 post allogeneic HCT in patients who
had achieved complete remission and full chimerism were
predictive of relapse two months on average prior to overt
hematological relapse. Larger studies may ﬁnd potential role
of MCP-1 in predicting relapse post-transplant and devel-
opment of early strategies for prevention.246
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Background: Treatment of adult Philadelphia chromosome
positive acute lymphoblastic leukemia (Ph+ALL) remains a
challenge. Tyrosine kinase inhibitors (TKI’s) have greatly
improved treatment options for Ph+ALL, leading to an
increased number of patients eligible for curative hemato-
poietic stem cell transplant. A current induction regimen for
Ph+ALL is the combination of the targeted dual Abl/Src TKI
dasatinib and a corticosteroid. It is thought that corticoste-
roids work synergistically with TKI’s by modulating the BCL-2
family of proteins, leading to apoptosis. However corticoste-
roids have to be tapered after the ﬁrst 21 days of induction
due to signiﬁcant toxicities, particularly in older adults.
Meanwhile, patients remain on TKI monotherapy until the
time of transplant, rendering them susceptible to the devel-
opment of resistance. Recently BCL-2 inhibitors have been
shown to have single agent efﬁcacy in B cell malignancies
with relatively low toxicity and our lab has shown in vitro
effects in primary patient Ph+ALL samples (unpublished data).
Therefore we investigated the potential combination of
dasatinib with the BCL-2 inhibitor ABT737 as a targeted
combination in Ph+ALL.
Methods: Drug efﬁcacy in vitro was determined using the
Ph+ALL cell line SupB15 and the CML cell line K562. Cells
were incubated with varying concentrations of dasatinib,
ABT737 or in combination for 72 hours. Cell viability was
assessed with the colorimetric MTS assay, and synergy was
calculated using Calculsyn software. Xenografted cells from a
patient with Ph+ALL were assessed under identical condi-
tions. Apoptosis was assessed with annexin V staining.
Expression of the BCL family proteins BCL-2 and MCL-1 were
assessed via immunoblot.
Results: The IC50 of dasatinib and ABT737 in SupB15
were 8.8nM and 5.9nM, respectively. The IC50 of equimolar
combination was 0.42nM, and synergistic with combination
index (CI) values between 0.15 and 0.49 (<1¼synergy).
Primary Ph+ALL xenograft cells showed a similar pattern of
synergy to the dasatinib + ABT737 combination, with CI
values between 0.01 and 0.38. Combination treatmentincreased apoptosis as measured by Annexin V staining. In
contrast, the CML cell line K562 was not sensitive to ABT737
as a single agent and there was no enhanced efﬁcacy by
adding this agent to dasatinib, suggesting this combination is
speciﬁc for Ph+ALL. This was supported by increased BCL-2
and low MCL-1 protein expression in SupB15 and xeno-
grafted Ph+ ALL cells, whereas K562 had low expression of
BCL-2 and high levels of MCL-1.
Conclusions: These data verify that the combination of
BCL-2 and BCR-Abl targeting in Ph+ ALL is synergistic in vitro
laying the foundation for further evaluation in vivo for adult
Ph+ALL. Combination targeted therapies may offer the po-
tential for greater and longer responses without the mor-
bidity associated with cytotoxic chemotherapy, particularly
in older adults.247
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Background: Ex-vivo expansion of CBT-cells with CD3/28
co-stimulatory beads, IL-2 & IL-7 & subsequent priming
against leukemia cell lines using IL-15 created speciﬁc CTLs.
[1, 2]
Hypothesis: We hypothesized (a) patient-derived AML-
speciﬁc PB auto CTLs could be generated (b) Tregs proportion
(CD4+CD25brightFoxP3+) & T-cell co-signaling markers’ gene
expressionwill be different between effective and ineffective
CTLs.
Methods: AML & auto T-cells were puriﬁed from PBMC of
AML patients admitted with acute blast crisis (n¼8). AML
blasts were sustained in Serum-Free media (STEMCELL
Tech) with MSC support & cytokines (IL-3, SCF, FLT3L,
GMCSF, IL-4). T-cells were expanded in culture for 2 weeks
as reported [1, 2] & subsequently primed with g-irradiated
auto AML weekly X 3 with IL15 & CD28ab [BD Biosciences].
At the end of week 3 (EOW3), cytotoxicity was assessed
against AML and irrelevant targets - IM9 & U937 cell lines,
at an E:T ratio of 40:1, 20:1, 10:1 & 5:1 using DELFIA
EuTDA assay.[2] IFN-g ELISPOT assay against same targets
was done.[2] RT-qPCR analysis was done on T-cells before &
after priming, with Power SYBR Green master mix (Thermo
Fisher) & StepOne Plus system (Life Tech). Student t-test
compared the groups.
Results:
1. T-cells expanded in all samples (n¼8) by median of
155-fold (range 11-489) at EOW3.
2. ELISPOT assay was positive in 4/8 samples. [Fig 1]
3. CTL assay was difﬁcult to standardize for AML blasts
due to high degree of spontaneous apoptosis (>30%
spontaneous release [SR]).
i. 2/8 samples were evaluable (SR<30%).
ii. Both samples showed AML-speciﬁc lysis. [Fig 2]
4. Overall, AML-speciﬁc auto CTLs could be generated in 5
of 8 samples based on ELISPOT & CTL assays.
